Phase 1/2 Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer

Trial Profile

Phase 1/2 Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary) ; Gemcitabine (Primary) ; Irinotecan (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 15 Jun 2017 Planned number of patients changed from 42 to 50.
    • 15 Apr 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top